 |
|
|
| |
Resistance Analysis at Week 48 of Daily Doravirine/Islatravir (100 mg/0.25 mg) vs Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Blinded Phase 3 Study in Adults Initiating Treatment for HIV-1
|
| |
| |
Glasgow 2026 Nov 8-11
Tracy L. Diamond*; Uchechukwu Nwoke; Tarak Patel; Yayun Xu; Stephanie O. Klopfer; Mary Vesnesky; Luisa M. Stamm; Michelle C. Fox; Mary L. Pisculli; Ernest Asante-Appiah
Merck & Co., Inc., Rahway, NJ, USA
|
| |
|
|
|
|
|
